Compare Stocks

Date Range: 

 Turning Point TherapeuticsApellis PharmaceuticalsNektar TherapeuticsLegend BiotechAtea Pharmaceuticals
SymbolNASDAQ:TPTXNASDAQ:APLSNASDAQ:NKTRNASDAQ:LEGNNASDAQ:AVIR
Price Information
Current Price$64.96$47.07$20.10$28.58$21.32
52 Week RangeBuyBuyHoldBuyBuy
MarketRank™
Overall Score1.71.61.51.32.0
Analysis Score3.53.43.03.53.5
Community Score3.12.73.02.34.6
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.70.00.0
Earnings & Valuation Score0.00.00.00.61.9
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyBuy
Consensus Price Target$153.71$130.08$25.29$49.00$69.33
% Upside from Price Target136.63% upside176.35% upside25.80% upside71.45% upside225.20% upside
Trade Information
Market Cap$3.19 billion$3.79 billion$3.66 billion$3.80 billion$1.76 billion
Beta1.231.471.76N/AN/A
Average Volume372,503653,5221,189,766354,053502,039
Sales & Book Value
Annual RevenueN/AN/A$114.62 million$64.39 millionN/A
Price / SalesN/AN/A31.9759.04N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$11.28 per share$0.46 per share$7.99 per shareN/AN/A
Price / BookN/AN/A2.52∞N/A
Profitability
Net Income$-72,130,000.00$-304,710,000.00$-440,670,000.00$-132,970,000.00N/A
EPS($2.99)($4.64)($2.52)N/AN/A
Trailing P/E RatioN/AN/AN/A0.000.00
Forward P/E RatioN/AN/AN/AN/A6.04
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-269.05%-543.73%N/A
Return on Equity (ROE)-23.81%-336.93%-30.74%-205.60%N/A
Return on Assets (ROA)-23.08%-78.28%-22.63%-43.03%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A3.34%N/AN/AN/A
Current Ratio35.45%9.86%8.25%4.88%N/A
Quick Ratio35.45%9.86%8.15%4.87%N/A
Ownership Information
Institutional Ownership Percentage81.31%81.20%95.32%18.92%N/A
Insider Ownership Percentage23.20%9.50%2.99%N/AN/A
Miscellaneous
Employees14237471880039
Shares Outstanding49.15 million80.50 million182.30 million133.01 million82.74 million
Next Earnings Date8/9/2021 (Estimated)7/30/2021 (Estimated)8/5/2021 (Estimated)N/A5/13/2021 (Confirmed)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
Atea Pharmaceuticals (AVIR) Scheduled to Post Earnings on ThursdayAtea Pharmaceuticals (AVIR) Scheduled to Post Earnings on Thursday
americanbankingnews.com - May 7 at 9:15 AM
Atea Pharmaceuticals to Host First Quarter Financial Results Conference Call on May 13, 2021Atea Pharmaceuticals to Host First Quarter Financial Results Conference Call on May 13, 2021
finance.yahoo.com - May 6 at 11:17 AM
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month Low at $23.35Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month Low at $23.35
americanbankingnews.com - May 3 at 11:46 AM
Atea Pharmaceuticals Inc. (NASDAQ:AVIR) Forecast to gain 199.47% to hit Consensus price targetAtea Pharmaceuticals Inc. (NASDAQ:AVIR) Forecast to gain 199.47% to hit Consensus price target
marketingsentinel.com - May 3 at 9:59 AM
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Sees Large Growth in Short InterestAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Sees Large Growth in Short Interest
americanbankingnews.com - May 2 at 6:24 AM
Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 ...Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 ...
apnews.com - April 29 at 10:18 AM
Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19
finance.yahoo.com - April 29 at 10:18 AM
Atea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With DosingAtea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With Dosing
finance.yahoo.com - April 29 at 10:18 AM
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is up 39.13% since its low, and it’s only getting startedAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) is up 39.13% since its low, and it’s only getting started
stocksregister.com - April 28 at 1:39 PM
Atea Pharmaceuticals (NASDAQ:AVIR) Sees Large Volume IncreaseAtea Pharmaceuticals (NASDAQ:AVIR) Sees Large Volume Increase
americanbankingnews.com - April 28 at 1:20 PM
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) – Analysts See The Stock Differently TodayAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) – Analysts See The Stock Differently Today
marketingsentinel.com - April 28 at 8:38 AM
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 5.3% Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 5.3%
americanbankingnews.com - April 27 at 3:46 PM
Atea Pharmaceuticals (AVIR) Sees Hammer Chart Pattern: Time to Buy?Atea Pharmaceuticals (AVIR) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - April 22 at 10:34 AM
Atea Pharmaceuticals Enters Oversold Territory (AVIR)Atea Pharmaceuticals Enters Oversold Territory (AVIR)
nasdaq.com - April 21 at 5:40 PM
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 7.7%Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 7.7%
americanbankingnews.com - April 21 at 11:43 AM
UPDATE 1-Roche looking for new place to test COVID-19 pill after cases plummet in UKUPDATE 1-Roche looking for new place to test COVID-19 pill after cases plummet in UK
finance.yahoo.com - April 21 at 7:39 AM
Atea Pharmaceuticals, Inc.s (NASDAQ:AVIR) Lock-Up Period Will End on April 28thAtea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Lock-Up Period Will End on April 28th
americanbankingnews.com - April 21 at 1:14 AM
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Gap Up to $44.50Atea Pharmaceuticals (NASDAQ:AVIR) Shares Gap Up to $44.50
americanbankingnews.com - April 20 at 11:36 AM
Atea Pharmaceuticals Inc (AVIR)Atea Pharmaceuticals Inc (AVIR)
investing.com - April 18 at 10:49 PM
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Up 38.8% in MarchAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Up 38.8% in March
americanbankingnews.com - April 18 at 5:42 AM
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) shares surges 22.33% in a week – but can it keep rising?Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) shares surges 22.33% in a week – but can it keep rising?
marketingsentinel.com - April 17 at 10:02 AM
Atea Pharmaceuticals (AVIR) Is in Oversold Territory: Whats Next?Atea Pharmaceuticals (AVIR) Is in Oversold Territory: What's Next?
finance.yahoo.com - April 16 at 9:00 AM
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 6.4% Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 6.4%
americanbankingnews.com - April 15 at 12:50 PM
Atea Pharmaceuticals (NASDAQ:AVIR) PT Raised to $82.00Atea Pharmaceuticals (NASDAQ:AVIR) PT Raised to $82.00
americanbankingnews.com - April 13 at 3:44 PM
Atea Pharmaceuticals (NASDAQ:AVIR) Sees Unusually-High Trading VolumeAtea Pharmaceuticals (NASDAQ:AVIR) Sees Unusually-High Trading Volume
americanbankingnews.com - April 13 at 11:52 AM
DateCompanyBrokerageAction
4/13/2021Turning Point TherapeuticsHC WainwrightLower Price Target
4/6/2021Turning Point TherapeuticsRoth CapitalBoost Price Target
4/6/2021Turning Point TherapeuticsOppenheimerReiterated Rating
2/2/2021Turning Point TherapeuticsCanaccord GenuityBoost Price Target
1/12/2021Turning Point TherapeuticsJMP SecuritiesBoost Price Target
12/14/2020Turning Point TherapeuticsSVB LeerinkBoost Price Target
10/26/2020Turning Point TherapeuticsWells Fargo & CompanyBoost Price Target
5/5/2021Apellis PharmaceuticalsCredit Suisse GroupBoost Price Target
4/22/2021Apellis PharmaceuticalsThe Goldman Sachs GroupInitiated Coverage
1/8/2021Apellis PharmaceuticalsRaymond JamesBoost Price Target
12/10/2020Apellis PharmaceuticalsCowenBoost Price Target
12/4/2020Apellis PharmaceuticalsJPMorgan Chase & Co.Boost Price Target
12/1/2020Apellis PharmaceuticalsBMO Capital MarketsBoost Price Target
11/23/2020Apellis PharmaceuticalsSmith Barney CitigroupBoost Price Target
11/23/2020Apellis PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
11/19/2020Apellis PharmaceuticalsNeedham & Company LLCInitiated Coverage
10/9/2020Apellis PharmaceuticalsCantor FitzgeraldReiterated Rating
8/31/2020Apellis PharmaceuticalsStifel NicolausInitiated Coverage
6/16/2020Apellis PharmaceuticalsBTIG ResearchInitiated Coverage
5/28/2020Apellis PharmaceuticalsUBS GroupInitiated Coverage
5/7/2021Nektar TherapeuticsMizuhoReiterated Rating
3/1/2021Nektar TherapeuticsBenchmarkReiterated Rating
6/10/2020Nektar TherapeuticsCfraDowngrade
3/4/2020Nektar TherapeuticsBarclaysInitiated Coverage
2/28/2020Nektar TherapeuticsPiper SandlerReiterated Rating
2/28/2020Nektar TherapeuticsWilliam BlairReiterated Rating
4/26/2021Legend BiotechMorgan StanleyLower Price Target
8/11/2020Legend BiotechJefferies Financial GroupReiterated Rating
11/24/2020Atea PharmaceuticalsEvercore ISIInitiated Coverage
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.